531 related articles for article (PubMed ID: 23886182)
1. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
4. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
[TBL] [Abstract][Full Text] [Related]
5. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
Tang D; Xu S; Zhang Q; Zhao W
Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
[TBL] [Abstract][Full Text] [Related]
6. Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer?
Jones T; Neboori H; Wu H; Yang Q; Haffty BG; Evans S; Higgins S; Moran MS
Ann Surg Oncol; 2013 Sep; 20(9):2866-72. PubMed ID: 23661183
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of triple-negative versus non-triple-negative breast cancers managed with breast-conserving therapy.
Bhatti AB; Khan AI; Siddiqui N; Muzaffar N; Syed AA; Shah MA; Jamshed A
Asian Pac J Cancer Prev; 2014; 15(6):2577-81. PubMed ID: 24761867
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of biological behavior between triple-negative breast cancer and non-triple- negative breast cancer].
Ma JG; Wang NJ; Yu WJ
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1729-32. PubMed ID: 22027778
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic and demographic evaluation of triple- negative breast cancer patients among a turkish patient population: a single center experience.
Somali I; Ustaoglu BY; Tarhan MO; Yigit SC; Demir L; Ellidokuz H; Erten C; Alacacioglu A
Asian Pac J Cancer Prev; 2013; 14(10):6013-7. PubMed ID: 24289617
[TBL] [Abstract][Full Text] [Related]
11. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
[TBL] [Abstract][Full Text] [Related]
12. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.
Pang H; Lu H; Song H; Meng Q; Zhao Y; Liu N; Lan F; Liu Y; Yan S; Dong X; Cai L
Cancer Epidemiol; 2013 Dec; 37(6):985-92. PubMed ID: 24012693
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and survival analysis of very young (age<35) breast cancer patients.
Wei XQ; Li X; Xin XJ; Tong ZS; Zhang S
Asian Pac J Cancer Prev; 2013; 14(10):5949-52. PubMed ID: 24289606
[TBL] [Abstract][Full Text] [Related]
14. Om.breast cancer in very young women aged 25 year-old or below in the center of Tunisia and review of the literature.
Ben Abdelkrim S; Fathallah K; Rouatbi R; Ayachi M; Hmissa S; Mokni M
Pathol Oncol Res; 2015 Jul; 21(3):553-61. PubMed ID: 25962349
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.
Nishimiya H; Kosaka Y; Yamashita K; Minatani N; Kikuchi M; Ema A; Nakamura K; Waraya M; Sengoku N; Tanino H; Kuranami M; Watanabe M
Anticancer Res; 2014 Jan; 34(1):259-68. PubMed ID: 24403472
[TBL] [Abstract][Full Text] [Related]
16. Outcome of non-metastatic male breast cancer: 118 patients.
Arslan UY; Oksüzoğlu B; Ozdemir N; Aksoy S; Alkış N; Gök A; Kaplan MA; Gümüş M; Berk V; Uncu D; Baykara M; Colak D; Uyetürk U; Türker I; Işıkdoğan A
Med Oncol; 2012 Jun; 29(2):554-60. PubMed ID: 21573973
[TBL] [Abstract][Full Text] [Related]
17. Novel prognostic markers for patients with triple-negative breast cancer.
Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
[TBL] [Abstract][Full Text] [Related]
18. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.
Montagna E; Maisonneuve P; Rotmensz N; Cancello G; Iorfida M; Balduzzi A; Galimberti V; Veronesi P; Luini A; Pruneri G; Bottiglieri L; Mastropasqua MG; Goldhirsch A; Viale G; Colleoni M
Clin Breast Cancer; 2013 Feb; 13(1):31-9. PubMed ID: 23098574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
